Paragraph 4!

ArticleMedicine Guanlan

On November 15th, Nuocheng Jianhua announced that the company's self-developed new protein tyrosine phosphatase SHP2 allosteric inhibitor ICP-189 has been approved by the US FDA for clinical research, becoming the company's fourth clinical innovation approved in the United States Medicine
.

ICP-189 was developed for the treatment of solid tumors.
It can be used as monotherapy and/or combination therapy with other anti-tumor drugs.
It aims to provide new clinical treatments for solid tumors such as lung cancer, head and neck cancer and gastrointestinal tumors
.

Preclinical studies have shown that ICP-189 is a highly selective oral SHP2 allosteric inhibitor, with good selectivity to other phosphatases
.

On October 19th, Nuocheng Jianhua announced that ICP-189 has been approved by the China National Medical Products Administration (NMPA) to conduct clinical trials.
This is a phase 1a/1b open, single-arm, multi-center study conducted in China It aims to evaluate the safety, tolerability, pharmacokinetic characteristics and effectiveness of ICP-189 single agent and combination therapy in patients with advanced solid tumors
.

(The original text has been deleted)

Reference materials:

[1] The new SHP2 allosteric inhibitor ICP-189 independently developed by Nuocheng Jianhua was approved by the US FDA for clinical research.